S-1: Celularity S-1: 14M Share Resale, Going Concern Risk

Sentiment:

Registration Statement for Resale 31 December 2025 9:15 PM

Celularity Inc. filed an S-1 registration statement for the resale of up to 14,078,938 Class A Common Stock by selling stockholders, while facing substantial doubt about its ability to continue as a going concern.

Capital raiseOn December 19, 2025, the company entered into a Senior Secured Note Financing for $7,000,000 principal and a Convertible Note Financing for $3,000,000 principal with Philip & Daniele Barach Family Trust.The company may sell up to an aggregate of $8,400,000 in principal amount of additional Senior Notes before June 19, 2026.The December Investor may purchase up to an aggregate of $2,000,000 of additional Convertible Notes, and the company may sell up to an aggregate of $6,200,000 in principal amount of Convertible Notes before June 19, 2026.On October 24, 2025, the company entered into a securities purchase agreement for up to $6,666,667 stated value of Series A Convertible Preferred Stock and accompanying warrants, with an initial tranche closing for approximately $2 million gross proceeds.On July 21, 2025, the company issued a promissory note in the aggregate principal amount of $6,812,230 to Tan Sri Lim Kok Thay.On July 14, 2025, the company issued 1,230,769 shares of Class A Common Stock and warrants in a private placement for a purchase price of $1.625 per share.On June 23, 2025, the company sold 739,284 shares of Class A Common Stock at a purchase price of $1.40 per share in a private placement.On March 13, 2024, the company entered into a Securities Purchase Agreement (SEPA) with YA II PN, LTD, granting the right to sell up to $10.0 million of Class A Common Stock, and issued a $3.15 million convertible promissory note.On November 25, 2024, the company sold $750,000 in unsecured senior convertible notes and warrants.The company will not receive proceeds from the sale of shares by the selling stockholders in this offering, but could receive approximately $28.2 million from the cash exercise of 11,732,657 warrants.

Worse than expectedThe auditor's report for the year ended December 31, 2024, included an explanatory paragraph about the existence of substantial doubt concerning the company's ability to continue as a going concern.The company has incurred net losses in every period since its inception and anticipates incurring substantial net losses in the future.The company will need substantial additional financing to develop its therapeutics and implement its operating plans.There is a risk that the company may not have cash available to make interest or principal payments on its indebtedness when due, which could force it to seek protection under the provisions of the U.S. Bankruptcy Code.

Summary

Celularity Inc. is a regenerative and cellular medicines company focused on addressing aging-related diseases, including cancer and degenerative diseases.
The S-1 filing registers up to 14,078,938 shares of Class A Common Stock for resale by identified selling stockholders.
The company will not receive any proceeds from the sale of these shares by selling stockholders.
However, the company could receive approximately $28.2 million if all 11,732,657 warrants offered for resale are exercised for cash.
As of December 30, 2025, the closing price of Celularity's Class A Common Stock on The Nasdaq Capital Market was $1.125 per share.
The company's business includes advanced biomaterial products (e.g., Biovance 3L for soft tissue repair), contract manufacturing services, and a fee-based biobanking business.
Pipeline updates include a 510(k) application for Celularity Tendon Wrap (CTW) submitted in August 2025, with objectives for FUSE Bone Void Filler 510(k) in H2 2026 and Celularity Placental Matrix (CPM) 510(k) in H2 2027.
Celularity is actively assessing opportunities to supply its mesenchymal-like adherent stromal cells (MLASCs) cell therapy product candidates (PDA 001 for Crohn's disease and PDA 002 for diabetic foot ulcer) in states with expanded access, such as Florida.
The company has a robust global intellectual property portfolio comprising over 290 patents and patent applications.
As of December 26, 2025, Celularity had 28,837,787 shares of Class A Common Stock outstanding and $4.4 million in outstanding secured debt.
The company has incurred net losses since its inception and anticipates substantial net losses in the future, with auditors noting substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 2

Explanation: The company faces substantial doubt about its ability to continue as a going concern, has a history of net losses, and requires significant additional financing. While there is pipeline progress and potential for warrant exercise proceeds, these are overshadowed by severe financial risks and operational challenges.

Positives

Active development pipeline for advanced biomaterial products, including a 510(k) application submitted for Celularity Tendon Wrap (CTW) in August 2025.
Strategic assessment of opportunities to supply MLASCs cell therapy product candidates (PDA 001 and PDA 002) in states with expanded access, such as Florida, which enacted relevant legislation on July 1, 2025.
Robust global intellectual property portfolio comprising over 290 patents and patent applications.
Potential to receive approximately $28.2 million in gross proceeds from the cash exercise of 11,732,657 warrants.
Experienced management team with over two decades of background in placental-derived technology.

Negatives

The company will not receive any proceeds from the sale of Class A Common Stock by the selling stockholders in this offering.
Uncertainty regarding the timing and amount of cash proceeds from warrant exercises, with the possibility that warrants may expire unexercised.
The company has incurred net losses in every period since its inception and anticipates substantial net losses in the future.
Auditors have included an explanatory paragraph about substantial doubt concerning the company's ability to continue as a going concern.
Requires substantial additional financing to develop therapeutics and implement operating plans, with a risk of being unable to complete development and commercialization if financing is not obtained.
Risk of not having sufficient cash to make interest or principal payments on its $4.4 million outstanding debt, potentially leading to acceleration of amounts due or seeking U.S. Bankruptcy Code protection.
Identified material weaknesses in internal control over financial reporting.
Potential adverse impact on business, financial condition, results of operations, and cash flows from the U.S. Department of Health and Human Services Centers for Medicare & Medicaid Services' CY 2026 Medicare Physician Fee Schedule, effective January 1, 2026.
Risk of delisting from Nasdaq if compliance with listing standards is not maintained.
Future sales and issuances of Class A Common Stock or rights to purchase Class A Common Stock will result in additional dilution for existing stockholders.
No intention to pay cash dividends for the foreseeable future.

Risks

There may not be an active trading market for Class A Common Stock, which may make it difficult to sell shares.
The market price of securities may be volatile, which could cause the value of an investment to decline.
Class A Common Stock may be delisted from Nasdaq if the company is not successful in maintaining compliance with Nasdaq's continued listing standards.
Future sales and issuances of Class A Common Stock or rights to purchase Class A Common Stock, or the exercise of outstanding options and warrants, will result in additional dilution of percentage ownership and could cause the stock price to fall.
The company does not intend to pay cash dividends for the foreseeable future.
The company has incurred net losses in every period since its inception and anticipates substantial net losses in the future.
Historical operating results indicate substantial doubt exists related to the company's ability to continue as a going concern.
The company will need substantial additional financing to develop its therapeutics and implement its operating plans; failure to obtain it may prevent completion of development and commercialization.
The company may not have cash available to make interest or principal payments on its indebtedness when due, potentially impacting liquidity, requiring operational modifications, or forcing protection under the U.S. Bankruptcy Code.
Significant decline in sales of currently commercialized biomaterial products without alternative products would seriously harm the business.
Placental-derived cellular therapy candidates represent a novel approach to cancer, infectious, and degenerative disease treatments that creates significant challenges.
Reliance on distribution arrangements for biomaterials products, with risks of incurring costs for unmet demand forecasts or inability to meet demand.
Operating its own manufacturing and storage facility requires significant resources; manufacturing or other failures could adversely affect clinical trials and commercial viability.
Significant competition from other biotechnology and pharmaceutical companies.
Risks associated with forming strategic alliances or entering into additional licensing arrangements.
Business could be materially adversely affected by health pandemics or epidemics.
Identified material weaknesses in internal control over financial reporting.
The U.S. Department of Health and Human Services Centers for Medicare & Medicaid Services' CY 2026 Medicare Physician Fee Schedule, effective January 1, 2026, may have a material adverse effect on the business.
The commercial biomaterials business may be impacted if The Centers for Medicare & Medicaid Services and Medicare Administrative Contractors do not reverse their Local Coverage Determination (LCD) for skin substitute grafts and cellular and tissue-based products before the LCD effective date of January 1, 2026.
The FDA regulatory approval process is lengthy and time-consuming, potentially causing significant delays in clinical development and regulatory review.
Reliance on donors of healthy human full-term post-partum placentas; inadequate supply could adversely impact development.
Reliance on third parties to conduct potential future clinical trials; failure to carry out duties or meet deadlines could prevent regulatory approval or commercialization.
Inadequate efforts to protect intellectual property could hinder effective competition.

Future Outlook

The company expects to advance the development of its FUSE Bone Void Filler with the objective of a 510(k) filing in the second half of 2026, and its Celularity Placental Matrix (CPM) with a 510(k) filing objective in the second half of 2027. It is actively assessing opportunities in Florida and other states to supply its mesenchymal-like adherent stromal cells (MLASCs) cell therapy product candidates, PDA 001 and PDA 002, for use in accordance with state law. When sufficiently capitalized, the company plans to complete safety and efficacy assessments to determine progress to Phase III clinical trials for PDA 002 in diabetic foot ulcer and PDA 001 in Crohn's disease. Celularity also intends to explore opportunities to diversify its biobanking business, including adult cell banking. Management anticipates incurring substantial net losses in the future and does not intend to pay cash dividends for the foreseeable future.

Management Comments

"Our goal is to ensure all individuals have the opportunity to live healthier longer."
"We believe that by harnessing the placentas unique biology and ready availability, we will be able to develop therapeutic solutions that address a significant unmet global need for effective, accessible and affordable therapeutics."
"Our current science is the product of the cumulative background and effort over two decades of our seasoned and experienced management team."
"We believe this know-how, expertise and intellectual property will drive the rapid development and, if approved, the commercialization of these potentially lifesaving therapies for patients with unmet medical needs."

Industry Context

Celularity operates within the regenerative and cellular medicines industry, focusing on placental-derived allogeneic advanced biomaterial products and cell therapies for aging-related diseases, including cancer and degenerative disorders. The industry is characterized by significant competition from other biotechnology and pharmaceutical companies. Recent legislative changes, such as a Florida law effective July 1, 2025, are expanding access to stem cell and other cell therapies not yet FDA-approved, creating new market opportunities for companies like Celularity. However, the industry also faces regulatory challenges, including potential adverse impacts from changes in Medicare reimbursement policies, such as the U.S. Department of Health and Human Services Centers for Medicare & Medicaid Services' proposed CY 2026 Medicare Physician Fee Schedule, which could affect payment rates for skin substitute products.

Comparison to Industry Standards

The filing does not provide specific comparisons to comparable companies, projects, or results within the industry.
It generally states that the company faces 'significant competition from other biotechnology and pharmaceutical companies' but does not offer detailed benchmarks or specific competitive analysis against industry standards.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Structure	The board of directors is divided into three classes (Class I, Class II, and Class III), with directors serving staggered three-year terms.	N/A	Staggered board terms can make it more difficult for stockholders to change a majority of the board, potentially entrenching current management.
Voting Rights	There is no cumulative voting for the election of directors.	N/A	Lack of cumulative voting means holders of more than 50% of shares voted can elect all directors, limiting minority shareholder influence.
Stockholder Meeting Call Rights	Special meetings of stockholders may only be called by a majority vote of the board of directors, the Chairperson of the board, or the Chief Executive Officer.	N/A	Restricts stockholders' ability to call special meetings, potentially limiting their power to address urgent matters or propose changes outside of annual meetings.
Stockholder Proposal Requirements	Bylaws include advance notice requirements for stockholders seeking to bring business or nominate directors at annual meetings.	N/A	These provisions may preclude stockholders from bringing matters before annual meetings or making director nominations without sufficient prior notice, potentially limiting stockholder activism.
Capital Structure Flexibility	The company has authorized but unissued Class A Common Stock and preferred stock available for future issuances without stockholder approval.	N/A	Provides flexibility for future capital raises, acquisitions, and employee benefit plans, but also poses a risk of dilution to existing stockholders without their direct approval.
Forum Selection	The Certificate of Incorporation includes exclusive forum selection clauses, designating the Delaware Court of Chancery as the sole forum for certain corporate claims and federal district courts for Securities Act claims.	N/A	Aims to provide increased consistency in the application of Delaware law and federal securities law, potentially reducing litigation costs, but may discourage lawsuits against directors and officers.
Anti-Takeover Provisions	The company is subject to Section 203 of the DGCL, which regulates corporate takeovers by preventing certain business combinations with interested stockholders for three years.	N/A	Makes it more difficult for a person to effect various business combinations without board approval, potentially protecting the company from hostile takeovers but also limiting opportunities for stockholders to realize a premium for their shares.
Indemnification	Indemnification agreements have been entered into with each director and executive officer to provide contractual indemnification to the fullest extent permitted by the DGCL.	N/A	Aims to attract and retain qualified directors and officers by protecting them from liabilities, but may reduce their personal accountability for certain actions.

Related Party Transactions

Philip & Daniele Barach Family Trust (December Investor), where Philip Barach is the Trustee, provided a $7,000,000 Senior Secured Non-Convertible Promissory Note and a $3,000,000 Convertible Promissory Note on December 19, 2025, along with associated warrants.
Resorts World Inc Pte Ltd (RWI), where Hiu Woon Yau is a director and Tan Sri Lim Kok Thay is an indirect beneficial owner of its largest stockholder, has provided multiple senior secured loans and received various warrants.
C.V. Starr & Co., Inc., where John Shannon is the Chief Investment Officer, has provided bridge loans and received warrants, some of which were repriced.
Tan Sri Lim Kok Thay, a former member of the board of directors, was issued a $6,812,230 promissory note, a warrant to purchase 3,700,000 shares, and 2,531 shares of Class A Common Stock on July 21, 2025.
Dragasac Limited, an indirect wholly-owned subsidiary of Genting Berhad (where Tan Sri Lim Kok Thay serves as Chief Executive and Chairman), participated in a private placement and had warrants amended.
Dr. Robert J. Hariri, the company's Chief Executive Officer and Chairman, subscribed for $2.0 million in a March 20, 2023, private placement of Class A Common Stock and warrants.

Stakeholder Impact

Shareholders face significant dilution risk from future equity issuances and warrant/option exercises, potential for stock price volatility, risk of delisting from Nasdaq, and no expectation of cash dividends in the foreseeable future. The investment carries a high degree of risk, with substantial doubt about the company's ability to continue as a going concern.
Creditors face uncertainty regarding the company's ability to make interest and principal payments on its $4.4 million outstanding debt, potentially leading to lenders enforcing security interests or the company seeking bankruptcy protection.
Customers of biomaterials products may be impacted by changes in Medicare reimbursement rates due to new payment methodologies from CMS, which could affect product accessibility or pricing.
Employees, while not explicitly detailed, may face risks to job security, future compensation, or equity value due to the company's financial instability and 'going concern' warning.

Next Steps

Advance the development of FUSE Bone Void Filler with the objective of a 510(k) filing in the second half of 2026.
Advance the development of Celularity Placental Matrix (CPM) with the objective of a 510(k) filing in the second half of 2027.
Actively assess opportunities in Florida and elsewhere to supply MLASCs cell therapy product candidates PDA 001 and PDA 002 to physicians in accordance with state law.
Complete safety and efficacy assessment to determine progress to a Phase III clinical trial of MLASCs cell therapy product candidate PDA 002 in diabetic foot ulcer and PDA 001 in Crohn's disease, when sufficiently capitalized.
Explore opportunities to diversify the biobanking business, including adult cell banking.
Prepare and file with the SEC a registration statement covering the Senior Note Warrant and Convertible Note Warrant on or prior to 45 calendar days following December 19, 2025.
Use best efforts to cause the registration statement covering the Senior Note Warrant and Convertible Note Warrant to be declared effective as promptly as practicable, but no later than 90 calendar days (or 120 days in case of full SEC review) following December 19, 2025.
Keep this prospectus effective until the earlier of the date on which the securities may be resold by the Selling Stockholders without registration or all of the securities have been sold.

Key Dates

Date	Description
1998	Anthrogenesis Corporation (Lifebank) founded by Robert J. Hariri.
2002	Anthrogenesis Corporation acquired by Celgene Corporation.
August 15, 2017	Celularity Inc. acquired Anthrogenesis Corporation from Celgene Corporation.
August 24, 2018	GX Acquisition Corp. incorporated in Delaware.
May 17, 2019	Registration Statement on Form 8-A filed for Class A Common Stock description.
May 20, 2019	Warrant Agreement between GX Acquisition Corp. and Continental Stock Transfer & Trust Company.
January 8, 2021	Merger Agreement and Plan of Reorganization signed between GX Acquisition Corp. and Legacy Celularity.
July 16, 2021	Merger consummated; GX Acquisition Corp. changed name to Celularity Inc.
October 4, 2021	Celularity Inc. 2021 Equity Incentive Plan filed.
April 1, 2022	Employment Agreements for Stephen A. Brigido and John R. Haines became effective.
January 25, 2023	Amendment to the Employment Agreement for Robert J. Hariri.
March 17, 2023	Loan agreement with C.V. Starr & Co., Inc. for $5,000,000 net, and issuance of warrants to purchase 75,000 shares at $7.10 per share.
March 20, 2023	Private placement of 938,183 shares and accompanying warrants, including $2.0 million subscribed by Dr. Robert Hariri.
May 16, 2023	Senior secured loan agreement (RWI Bridge Loan) with Resorts World Inc Pte Ltd (RWI) for $6,000,000 net.
May 17, 2023	Private placement of 581,394 shares and accompanying warrants.
June 20, 2023	C.V. Starr & Co., Inc. granted additional warrants to acquire 50,000 shares at $8.10 per share.
June 21, 2023	Amended and restated senior secured loan agreement with RWI, providing an additional $6,000,000 net loan and issuance of warrants to acquire 300,000 shares at $8.10 per share.
September 18, 2023	Issued 270,731 shares of Class A Common Stock to YA II PN, Ltd.
December 21, 2023	Settlement and release agreement with Palantir Technologies Inc., resulting in issuance of 60,584 shares.
January 10, 2024	Issued 20,000 shares of Class A Common Stock to Palantir Technologies Inc.
January 12, 2024	Second amended and restated senior secured loan agreement with RWI, providing an additional $15.0 million net loan and issuance of warrants to acquire 1,650,000 shares at $2.4898 and 1,350,000 shares at $2.988 (subsequently repriced to $2.844).
January 12, 2024	Private placement with Dragasac Limited for 2,141,098 shares and 535,274 warrants at $2.4898 per share.
February 16, 2024	Second Amendment to the Amended and Restated Employment Agreement with Robert J. Hariri, and amendments to employment agreements with Stephen Brigido and John Haines.
March 13, 2024	Entered into a Second Forbearance Agreement with RWI, issuing a warrant to acquire 300,000 shares at $5.895 per share.
March 13, 2024	Entered into a forbearance agreement with C.V. Starr & Co. Inc., amending the exercise price of certain warrants to $5.895 per share.
March 13, 2024	Entered into a Securities Purchase Agreement (SEPA) with YA II PN, LTD for up to $10.0 million of Class A Common Stock and issued a $3.15 million convertible promissory note.
May 6, 2024	Issued 40,584 shares of Class A Common Stock to Palantir Technologies Inc.
July 30, 2024	Deloitte & Touche LLP's audit report for the year ended December 31, 2023.
September 13, 2024	Yorkville convertible promissory note conversion price reset to $2.7546.
November 11-14, 2024	Issued 478,881 shares of Class A Common Stock to Yorkville in connection with the conversion of $1.3 million in notes.
November 18, 2024	Issued 59,176 shares of Class A Common Stock to a former employee.
November 25, 2024	Securities purchase agreement for unsecured senior convertible notes and warrants, selling $750,000 in notes.
December 31, 2024	EisnerAmper LLP's audit report for the year ended December 31, 2024, included a going concern explanatory paragraph.
January 3, 2025	Issued 21,739 shares of Class A Common Stock to a former employee.
January 24, 2025	Issued 1,188,255 shares of Class A Common Stock upon warrant exercise.
February 12, 2025	Binding term sheet with RWI for forbearance extension, issuance of 500,000 warrants at $2.844, and repricing of certain outstanding RWI warrants.
February 12, 2025	Binding term sheet with C.V. Starr & Co., Inc. for forbearance extension, issuance of 100,000 warrants at $1.692, and repricing of certain outstanding C.V. Starr warrants.
February 29, 2025	Issued 100,000 shares of Class A Common Stock to Yorkville.
May 8, 2025	Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC.
May 19, 2025	Issued 50,000 shares of Class A Common Stock to a consultant.
May 20, 2025	Issued 100,000 shares of restricted Class A Common Stock to Yorkville.
June 20, 2025	Issued 12,000 shares of Class A Common Stock to a consultant.
June 23, 2025	Sold 739,284 shares of Class A Common Stock at $1.40 per share in a private placement.
June 25, 2025	Issued 490,632 shares of Class A Common Stock to holders of unsecured senior convertible notes after amending conversion price to $1.60.
July 1, 2025	Florida law expanding access to stem cell and other cell therapies went into effect.
July 14, 2025	Issued 1,230,769 shares of Class A Common Stock and warrants at $1.625 per share to an institutional investor.
July 16, 2025	Centers for Medicare & Medicaid Services published its CY 2026 Medicare Physician Fee Schedule Proposed Rule.
July 21, 2025	Issued a promissory note for $6,812,230 and a warrant to purchase 3,700,000 shares at $2.528 per share to Tan Sri Lim Kok Thay, and issued 2,531 shares of Class A Common Stock.
August 2025	Submitted a 510(k) application for Celularity Tendon Wrap (CTW).
August 13, 2025	Asset Purchase Agreement and License Agreement with Celeniv Pte. Ltd.
August 29, 2025	Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025, and June 30, 2025, filed with the SEC.
October 24, 2025	Entered into a securities purchase agreement for up to $6,666,667 stated value of Series A Convertible Preferred Stock and warrants; initial tranche closed for approximately $2 million gross proceeds.
November 14, 2025	Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, filed with the SEC.
December 16, 2025	Issued warrants to purchase 50,000 shares of Class A Common Stock to Helena Global Investment Opportunities 1 Ltd.
December 19, 2025	Entered into Senior Securities Purchase Agreement for a $7,000,000 Senior Secured Non-Convertible Promissory Note and a warrant for 2,448,917 shares with Philip & Daniele Barach Family Trust.
December 19, 2025	Entered into Convertible Note Purchase Agreement for a $3,000,000 Convertible Note and a warrant for 1,258,740 shares with Philip & Daniele Barach Family Trust.
December 24, 2025	Last reported sale price of Class A Common Stock on Nasdaq was $1.32 per share.
December 26, 2025	Company had 28,837,787 shares of Class A Common Stock outstanding.
December 30, 2025	Closing price of Class A Common Stock on Nasdaq was $1.125 per share.
December 31, 2025	Date of this preliminary prospectus.
January 1, 2026	U.S. Department of Health and Human Services Centers for Medicare & Medicaid Services' CY 2026 Medicare Physician Fee Schedule is set to take effect.
February 15, 2026	Maturity date of the Starr Bridge Loan extended to this date.
March 21, 2026	Maturity date of the promissory note issued to Tan Sri Lim Kok Thay.
June 19, 2026	Senior Note Warrant and Convertible Note Warrant become exercisable.
H2 2026	Objective for 510(k) filing for FUSE Bone Void Filler.
December 31, 2026	Maturity date of the Convertible Note.
H2 2027	Objective for 510(k) filing for Celularity Placental Matrix (CPM).
March 17, 2028	Warrants issued to C.V. Starr & Co., Inc. in March 2023 expire.
June 20, 2028	Warrant issued to RWI in March 2024 expires.
May 18, 2028	Warrants from May 2023 private placement expire.
March 24, 2028	Warrants from March 2023 private placement expire.
January 16, 2029	Warrants from Dragasac Limited private placement expire.
December 19, 2030	Senior Note Warrant and Convertible Note Warrant terminate.

Recommendation

strong sell

The filing explicitly states 'substantial doubt exists related to our ability to continue as a going concern' and highlights a history of net losses with anticipated future losses. The company requires 'substantial additional financing' and faces significant risks including potential delisting, inability to meet debt obligations, and high competition. While there is a pipeline and potential warrant exercise proceeds, these are insufficient to offset the severe financial distress and fundamental business risks outlined, making the stock a high-risk investment with a strong likelihood of further value erosion.

Keywords

Celularity, CELU, SEC Filing, S-1, Registration Statement, Resale Offering, Class A Common Stock, Warrants, Convertible Note, Biotechnology, Cellular Medicine, Regenerative Medicine, Biomaterials, Placental-derived, Cancer Therapy, Degenerative Diseases, Diabetic Foot Ulcer, Crohn's Disease, FDA Approval, Clinical Trials, Intellectual Property, Biobanking, Going Concern, Dilution, Nasdaq, Capital Raise, Debt Financing, Medicare Reimbursement, Risk Factors

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.